Quick Answer
Akari Therapeutics Plc reported Net Income of -$17.30 million for fiscal year 2025.
Akari Therapeutics Plc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$17.30M +12.6% |
-$19.79M -97.8% |
-$10.01M +43.6% |
-$17.75M -1.9% |
-$17.42M -2.0% |
-$17.08M -1.4% |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 +100.0% |
-$0.01 +0.0% |
| Total Assets | $47.89M -5.3% |
$50.56M +1061.0% |
$4.36M -68.5% |
$13.83M +18.7% |
$11.65M +20.3% |
$9.68M +17.6% |
| Cash and Equivalents | — | $2.60M -32.4% |
$3.85M -71.0% |
$13.25M +41.5% |
$9.36M +19.7% |
$7.82M +27.3% |
| Stockholders Equity | $28.33M +27.4% |
$22.23M +9807.0% |
-$229.0K -112.8% |
$1.79M -67.8% |
$5.55M +70.0% |
$3.27M -32.5% |
| R&D Expense | $2.81M -59.7% |
$6.98M +28.1% |
$5.45M -43.0% |
$9.56M +4.7% |
$9.13M +3.6% |
$8.82M +0.9% |
| Operating Income | -$17.27M +20.2% |
-$21.64M -28.8% |
-$16.81M +27.2% |
-$23.09M -34.1% |
-$17.21M +4.3% |
-$17.98M -6.0% |
| Shares Outstanding | 90.54B +70.2% |
53.19B +301.9% |
13.23B +77.8% |
7.44B +56.4% |
4.76B +23.7% |
3.85B +71.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$6.40M | -121.1% | -237.7% |
| Diluted EPS | September 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $45.38M | +1559.7% | -10.9% |
| Cash and Equivalents | June 30, 2025 | $2.71M | -35.1% | +5.0% |
| Stockholders Equity | September 30, 2025 | $22.69M | +438.9% | -11.4% |
| R&D Expense | September 30, 2025 | $249.0K | +74.1% | -62.7% |
| Operating Income | September 30, 2025 | -$7.40M | -153.0% | -137.4% |
| Shares Outstanding | September 30, 2025 | 65.23B | +168.6% | +0.0% |
- Akari Therapeutics Plc reported Net Income of -$17.30 million for fiscal year 2025.
- Akari Therapeutics Plc showed an increase of +12.6% in Net Income compared to the prior fiscal year.
- Akari Therapeutics Plc reported Diluted EPS of $0.00 per share for fiscal year 2025.
- Akari Therapeutics Plc reported Total Assets of $47.89 million for fiscal year 2025.
- Akari Therapeutics Plc showed a decrease of -5.3% in Total Assets compared to the prior fiscal year.
- Akari Therapeutics Plc reported Cash and Equivalents of $2.60 million for fiscal year 2024.
- Akari Therapeutics Plc showed a decrease of -32.4% in Cash and Equivalents compared to the prior fiscal year.
- Akari Therapeutics Plc reported Stockholders Equity of $28.33 million for fiscal year 2025.
- Akari Therapeutics Plc showed an increase of +27.4% in Stockholders Equity compared to the prior fiscal year.
- Akari Therapeutics Plc reported R&D Expense of $2.81 million for fiscal year 2025.
- Akari Therapeutics Plc showed a decrease of -59.7% in R&D Expense compared to the prior fiscal year.
- Akari Therapeutics Plc reported Operating Income of -$17.27 million for fiscal year 2025.
- Akari Therapeutics Plc showed an increase of +20.2% in Operating Income compared to the prior fiscal year.
- Akari Therapeutics Plc reported Shares Outstanding of 90.54 billion shares for fiscal year 2025.
- Akari Therapeutics Plc showed an increase of +70.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: